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Lower urinary tract symptoms (LUTS); (Abrams et al., 
2002) are highly prevalent in both male and female 
patients after stroke, ranging up to 94% (Tibaek et al., 
2008; Williams, Srikanth, Bird, & Thrift, 2012). The 
poststroke symptoms are nocturia (Tibaek et al., 2008; 
Williams et al., 2012), urgency, frequent daytime void-
ing, urge incontinence, incomplete bladder emptying, and 
urinary tract infection (Ruffion et al., 2013).
Stroke has a profound effect on quality of life. For 
patients with LUTS, the impact is also substantial, lead-
ing to increasing limitations in social and physical activi-
ties with psychological (anxiety, depression, and isolation) 
aspects (Tibaek et al., 2008) as well as increased risk 
of falls (Divani, Vazquez, Barrett, Asadollahi, & Luft, 
2009).
Pelvic floor muscle training (PFMT) is regarded as the 
first-line conservative treatment option for LUTSin neuro-
logically healthy men (Gormley et al., 2012; Hay-Smith, 
Berghmans, & Burgio, 2009; Hunter, Glazener, & Moore, 
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Abstract
The aim of the current study was to evaluate the effect of pelvic floor muscle training in men with poststroke 
lower urinary tract symptoms. Thirty-one poststroke men, median age 68 years, were included in this single-blinded 
randomized controlled trial. Thirty participants, 15 in each group, completed the study. The intervention consisted of 
3 months (12 weekly sessions) of pelvic floor muscle training in groups and home exercises. The effect was evaluated 
by the DAN-PSS-1 (Danish Prostate Symptom Score) questionnaire, a voiding diary, and digital anal palpation of 
the pelvic floor muscle. The DAN-PSS-1, symptom score indicated a statistical significant improvement (p < .01) in 
the treatment group from pretest to posttest, but not in the control group. The DAN-PSS-1, total score improved 
statistically significantly in both groups from pretest to posttest (treatment group: p < .01; control group: p = .03). 
The median voiding frequency per 24 hours decreased from 11 at pretest to 7 (36%; p = .04) at posttest and to 8 
(27%; p = .02) at follow-up in treatment group, although not statistical significantly more than the control group. The 
treatment group but not the control group improved statistically significantly in pelvic floor muscle function (p < .01) 
and strength (p < .01) from pretest to posttest and from pretest to follow-up (p = .03; p < .01). Compared with the 
control group the pretest to posttest was significantly better in the treatment group (p = .03). The results indicate 
that pelvic floor muscle training has an effect for lower urinary tract symptoms, although statistical significance was 
only seen for pelvic floor muscle.
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2007; Newman, Guzzo, Lee, & Jayadevappa, 2014). It has 
also shown positive effects on LUTS in women with 
neurological diseases (De Ridder, Vermeulen, Ketelaer, 
Van Poppel, & Baert, 1999; Lucio, D’Ancona, Lopes, 
Perissinotto, & Damasceno, 2014; Lucio et al., 2010; 
McClurg, Ashe, Marshall, & Lowe-Strong, 2006; Tibaek, 
Gard, & Jensen, 2005). In women with urinary inconti-
nence (UI) after a first stroke, 12 weeks of PFMT lead to 
significant reduction of UI leakage and frequency of day-
time voiding while pelvic floor muscle (PFM) function 
increased significantly (Tibaek et al., 2005).
The goal of PFMT in stroke patients is to improve the 
contribution to the sphincter closure mechanism by motor 
learning and PFM awareness, function, strength, dura-
tion, and functional training. Furthermore, it is debated if 
an improved PFM can inhibit involuntary detrusor con-
traction (Fowler & Griffiths, 2010; Panicker, Fowler, & 
Kessler, 2015; Seseke et al., 2006; Zhang et al., 2005).
Although PFMT is a noninvasive treatment with no 
known side effects or complications, no randomized con-
trolled trial (RCT) has evaluated its effect on poststroke 
LUTS in men. The aim of the current study was to evalu-
ate the effect of PFMT on poststroke LUTS in men.
Material and Method
This study was part of a large, multifaceted study. The 
study focused on PFMT in poststroke men with LUTS 
(Tibaek et al., 2015).
Participants
Between February 1, 2010 and December 31, 2012, med-
ical records from the Departments of Neurology at 
Glostrup and Herlev Hospitals, University of Copenhagen 
of poststroke men were successively screened according 
to inclusion and exclusion criteria. Inclusion criterion 
included (a) men, diagnosed with a stroke clinically 
defined according to the World Health Organization 
(1989) and confirmed by computed tomography or mag-
netic resonance imaging scan, (b) at least 1 month since 
their last stroke, (c) normal cognitive function (minimal 
mental examination score >25), (d) LUTS according to 
the International Continence Society definition (Abrams 
et al., 2002) with start or aggravation closely related to 
the stroke and measured by the Danish Prostatic Symptom 
Score (DAN-PSS-1) questionnaire (Meyhoff et al., 1993), 
(e) ability to walk independently indoors for at least 100m 
with or without walking aids, (f) outpatient and self-
transported, (g) ability to visit the toilet independently, 
and (h) age >18 years. Exclusion criterion included (a) 
prior history of LUTS surgery, pelvic surgery, or trauma; 
(b) more than two strokes (diagnosed at a hospital); (c) 
other severe neurological disease including dementia; (d) 
severe dysphasia; (e) severe psychiatric disease; (f) pros-
tate cancer; and (g) not speaking Danish or English.
Design
The design was an experimental prospective RCT using 
randomized, controlled, and single-blinded parallel 
groups. The trial started with a 4-week run-in period 
including an initial investigation sequence (pretest). This 
was followed by randomization to either a treatment 
group (TG) or a control group (CG).
After 12 weeks, the second investigation sequence 
was performed (posttest), with the final investigation 
sequence (follow-up) after a further 6 months. 
Randomization was based on a mathematical table deliv-
ered in blocks of 10 in sealed envelopes and managed by 
a person who did not participate further in the study.
Registration of variables from the pretest, posttest, and 
follow-up investigation sequences were managed by 
individuals (physiotherapists) who were blinded to the 
randomization code of the participants, while the physio-
therapist treating the participants with PFMT was 
unblinded. The participants randomized for CG were all 
offered a 12-week PFMT program after the trial. The par-
ticipants received verbal and written information and 
signed an informed consent before entry into the study. 
The study was approved by the Ethical Committee of 
Copenhagen County (H-B-2009-069) and registered in 
the Danish Register for Data protection and in the Clinical 
Trials.gov Protocol Registration System (Clinical Trials 
NTC01042249).
Intervention
The participants in the TG were treated in a systematic, 
controlled, intensive PFMT program over 3 months (12 
weekly sessions and 60 minutes per session) by the same 
specialized physiotherapist. The treatment program con-
sisted of the following topics: introduction (theory), 
home exercise, group treatment, and digital anal palpa-
tion of PFM. The PFMT program has been published pre-
viously (Tibaek et al., 2015). The participants in the CG 
followed the standard program of general rehabilitation 
without any specific LUTS treatment.
Outcome Measures
1. The DAN-PSS-1 questionnaire (primary out-
come). The DAN-PSS-1 questionnaire (Meyhoff 
et al., 1993) consists of 12 questions related to 
LUTS in the 2 weeks prior to response. Each 
question has two parts, Part A and Part B. In Part 
A, the participants are asked to state the frequency 
and severity of the symptoms (symptom score) 
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and in Part B, the impact on their daily life of the 
symptoms if present (bother score). The respon-
dents classify all answers in a four-ranked scale 
from 0 to 3 with zero being absence of symptoms 
or bother and three the maximum severity of 
symptoms or bother. The total DAN-PSS-1 index 
was calculated as symptom score × bother score. 
The DAN-PSS-1 questionnaire has been reported 
as reliable and valid in a sample of poststroke men 
and women (Tibaek & Dehlendorff, 2009; Tibaek, 
Jensen, Klarskov, Iversen, & Gard, 2006).
2. The voiding diary (primary outcome). A 3-day 
voiding diary in a modified version (Larsson, 
Abrams, & Victor, 1991) measured: (a) time and 
frequency of voiding, (b) number of incontinence 
episodes, and (c) number of pads used.
3. 24-Hour pad test (primary outcome). A 24-hour 
(h) pad test.
4. Digital anal palpation of PFM (secondary outcome).
a)  PFM function. Best of 3 attempts graduated 
on a 4-point ordinal scale 0 = no PFM con-
traction, 1 = partial PFM contraction, 2 = 
PFM contraction + cocontraction with other 
related muscles, 3 = isolated PFM contrac-
tion (Tibaek et al., 2005).
b)  PFM strength. Best of three attempts graded 0 
to 6 (nil, flicker, weak, moderate, good, strong, 
very strong) on a Danish version of the modi-
fied Oxford scale (Laycock, 1994). The partici-
pants were instructed to perform a maximal 
voluntary contraction of the pelvic floor muscle 
without cocontraction of other related muscles.
c)  PFM static endurance. The participants were 
instructed to maintain the contraction for as 
long as possible. Static endurance was the 
point of isometric fatigue at which the muscle 
contraction could no longer be maintained and 
was measured in seconds on a stopwatch.
d)  PFM dynamic endurance. Maximum number 
of 6-second PFM contractions with 6 sec-
onds of relaxation in between. Dynamic 
endurance is the number of contractions after 
which contraction can no longer be sustained. 
The cutoff value was 40 contractions.
The test procedure was standardized and involved digital 
examination of the anal sphincter. It was performed for 
all participants by the same PT for whom the randomiza-
tion code was blinded.
Statistical Analysis
Statistical analysis was carried out using IBM SPSS 
(Statistical Package of Social Science) version 20. Median 
and interquartile range (IQR) are presented for small sam-
ples. The null hypothesis between groups was tested by 
the Mann–Whitney U test and within groups using the 
Wilcoxon signed-rank test. In addition, the effect of PFMT 
was analyzed by comparing the change for each partici-
pant from test to test between the groups.
For all tests, the level for statistical significance was 
set to p < .05. Power calculations in which an assump-
tion of a decrease of two points at DAN-PSS-1, total 
score indicated that, with 90% power and a significance 




Medical records of 1,812 poststroke men were screened for 
inclusion (Figure 1) and 516 were invited to participate. 
Thirty-one participants were eligible and randomized.
Thirty participants, with a median age of 68 years 
(IQR: 60-74) completed the study, 15 in each group. At 
the 6-month follow-up, one participant from the CG 
dropped out.
Median PFMT sessions attendance rate in the TG was 
11 sessions (IQR: 10-12) corresponding to 92%.
Baseline Characteristics
Demographic baseline characteristics of the study group 
are presented in Table 1. Neurological, urological, and 
physical baseline characteristics are presented in Table 2. 
There were no statistically significant differences between 
the TG and CG in any of the baseline characteristics. The 
DAN-PSS-1 questionnaires were complete in all partici-
pants, while data were missing from 9 to 11 (30% to 
36%) participants for the 3-day voiding diary and 2 to 6 
(6% to 20%) participants regarding the digital anal pal-
pation of PFM.
The DAN-PSS-1 Questionnaire
The results measured on the DAN-PSS-1 questionnaire 
are presented in Table 3.
Symptom Score. At 3 months, the results demonstrated a 
statistically significant decrease (p < .01) in symptom 
score for the TG from pretest to posttest, but not in the 
CG, although a trend (p = .05) was noted. The difference 
between the groups was, however, not significant. At 
follow-up, the results demonstrated a significant decrease 
(p = .04) in symptom score from posttest to follow-up in 
the TG which, however, was not a statistically significant 
difference from the CG, indicating no long-lasting effect 
of the intervention.
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Bother Score. The results for bother score (Table 3) dem-
onstrated a statistically significant decrease in both groups 
with no significant difference between the improvement 
in the TG compared with the CG. At follow-up, the bother 
score results demonstrated a trend to statistical signifi-
cance (p = .06) in the TG from posttest to follow-up, but 
not in the CG. Furthermore, there was a significant differ-
ence (p = .02) in the CG from pretest to follow-up. 
Figure 1. Study profile.
Note. TG = treatment group; CG = control group.
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However, none of these differences between groups were 
statistically significant.
Total Score. At 3 months, the total score results (Figure 2) 
demonstrated a significant decrease in both the TG (p < 
.01) and CG (p = .03), but the decreases were not signifi-
cantly different from the decrease in the CG. At follow-
up, the total score increased significantly (p = .03) in the 
TG from posttest to follow-up, but not in the CG.
The Voiding Diary
The results measured on the 3-day voiding diary are pre-
sented in Table 3.
Frequency of Voidings per 24 Hours. At 3 months, the TG 
voidings per 24 hours demonstrated a reduction in median 
value from 11 at pretest to 7 at posttest. This decrease of 
four (36%) voidings per 24 hours was statistically signifi-
cant (p = .04) within the group. The median value of 
number of voidings in the CG was reduced insignificantly 
by three (27%) per 24 hours.
At follow-up, the TG median value indicated a statisti-
cally significant (p = .02) reduction by 3 (27%) from pre-
test to follow-up. However, for the CG, the median value 
was decreased by 1 (9%) and not significant.
No significant difference between TG and CG was 
demonstrated at pretest, posttest, and follow-up. Likewise, 
there was no significant difference between the groups.
Table 1. Demographic Baseline Characteristics of Poststroke Men.
Characteristic
Treatment group 
(n = 15), N (%)
Control group 
(n = 15), N (%) p Value
Age, yearsa 68 (57-73) 70 (64-75) .22
Previous medical history, diseases, and risk factors
 Stroke (one attack) 0 (0) 5 (33) .13
 Hypertension 4 (27) 5 (33) .78
 Transient ischemic attack 0 (0) 1 (7) .78
 Diabetes mellitus 2 (13) 1 (7) .78
 Coronary heart disease 3 (20) 0 (0) .37
 Other diseases (arthritis, fractures, muscular disorders, etc.) 5 (33) 5 (33) 1.00
 None 7 (47) 2 (13) .13
Smoking
 Smoker 2 (13) 2 (13) .49
 Former smoker 3 (20) 1 (7)  
 Never smoker 10 (67) 12 (80)  
Alcohol, no. of consumed units per week
 0 5 (33) 7 (47) .33
 0-6 5 (33) 6 (40)  
 7-13 2 (13) 1 (7)  
 14-21 2 (13) 0 (0)  
 >21 1 (7) 1 (7)  
Social status
 Employed 5 (33) 2 (13) .57
 Unemployed 0 (0) 0 (0) —
 Early retirement/sick leave >3 months 1 (7) 3 (20)  
 Retired 9 (60) 10 (67)  
Civil status
 Single/divorced 4 (27) 4 (27) .84
 Married/partnered 10 (67) 11 (73)  
 Widower 1 (7) 0 (0)  
Current use of medication
 Antiarrhythmics/antihypertensives 10 (67%) 6 (40%) .22
 Statins 12 (80%) 10 (67%) .54
 Anticoagulants/antithrombotics 12 (80%) 12 (80%) 1.00
 Hypoglycemics agents 1 (7%) 0 (0%) .77
 Analgesics 1 (7%) 1 (7%) 1.00
 Antidepressants 1 (7%) 0 (0%) .77
 Other 5 (33%) 7 (47%) .54
aMedian (interquartile range).
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Table 2. Neurological, Urological, and Physical Baseline Characteristics of Poststroke Men.
Characteristic
Treatment group  
(n = 15), N (%)
Control group  
(n = 15), N (%) p Value
Neurological
Minimental state examination score  
(maximum score = 30)a
29 (29-30) 29 (28-30) .22
Barthel Index (maximum score = 100)a 100 (100-100) 100 (100-100) .78
Time since last stroke, daysa 65 (50-87) 55 (50-63) .60
Result of stroke verification by CT or MRI scan
 Visible stroke at imaging 12 (80) 11 (73) .78
 No visible stroke at imaging, but clinical stroke 3 (20) 4 (27)  
Subtypes of stroke
 Infarct 13 (87) 10 (67) .74
 Hemorrhage 0 (0) 2 (13)  
 Infarct + hemorrhage 0 (0) 0 (0)  
 No infarct 1 (7) 0 (0)  
 No information 1 (7) 3 (20)  
Localization
 Left hemisphere 4 (27) 6 (40) .68
 Right hemisphere 6 (40) 7 (47)  
 Bilateral 2 (13) 0 (0)  
 Unclassified 2 (13) 2 (13)  
 No information 1 (7) 0 (0)  
Urological
Past history of LUTS
 None 12 (80) 11 (73) .51
 Pharmacological treatment 2 (13) 4 (27)  
 No information 1 (7) 0 (0)  
Current use of LUTSb medicine
 Overactive bladder 2 (13) 4 (27) .74
 Prostate 1 (7) 1 (7) —
 No medicine 12 (80) 10 (67) .78
Use of LUTS aids
 Pads 2 (13) 2 (13) 1.00
 Catheter 0 (0) 0 (0) —
 None 13 (87) 13 (87) 1.00
Physical activitya
Walking distance, meter 2,000 (1,000-5,000) 2,000 (1,000-4,000) .68
Sports/exercise, minutes per week 0 (0-0) 45 (0-120) .81
Use of walking aids
 Crutch 0 (0) 0 (0) .78
 Rollator 0 (0) 1 (7)  
 Other walking aids 0 (0) 0 (0)  
 None 15 (100) 14 (93)  
One leg stand, eyes open, secondsa
 Dominant leg 10 (5-29) 3 (11-15) .56
 Nondominant leg 29 (4-30) 10 (1-30) .12
Previous PFMT
 Yes 0 (0) 2 (13) .54
 No 15 (100) 13 (87)  
Note. CT = computed tomography; MRI = magnetic resonance imaging; PFMT = pelvic floor muscle training; LUTS = lower urinary tract symptoms.
aMedian (interquartile range). bThe Danish Prostate Symptom Score.
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Table 3. Results of Pelvic Floor Muscle Training Within and Between Groups measured on the Danish Prostate Symptom Score 




(n = 15) p Valuea p Valueb
DAN-PSS-1 questionnaire
Symptom score, median (interquartile range)
 Pretest (30/30) 9 (7-11) 10 (6-13) .51  
 Posttest (30/30) 6 (4-10) 5 (5-11) .74  
 Follow-up (30/30) 7 (4-13) 7 (2-12) .59  
 p Valuec <.01* .05 .93i
 p Valued .04* .46 .06ii
 p Valuee .15 .07 .59iii
Bother score, median (interquartile range)
 Pretest (30/30) 7 (4-9) 11 (6-13) .13  
 Posttest (30/30) 3 (3-5) 6 (3-12) .13  
 Follow-up (30/30) 3 (1-12) 6 (6-11) .91  
 p Valuec <.01* .01* .93i
 p Valued .06 .60 .13ii
 p Valuee .16 .02* .45iii
Total score, median (interquartile range)
 Pretest (30/30) 11 (7-14) 17 (8-24) .25  
 Posttest (30/30) 3 (1-7) 6 (4-22) .15  
 Follow-up (30/30) 5 (1-19) 8 (1-21) .88  
 p Valuec <.01* .03* .59i
 p Valued .03* .78 .10ii
 p Valuee .12 .09 .85iii
Voiding diary
Voiding frequency, total per 24 hours, median (interquartile range)
 Pretest (20/30) 11 (6-10) 11 (8-12) .97  
 Posttest (21/30) 7 (5-10) 8 (7-12) .25  
 Follow-up (19/30) 8 (5-11) 10 (7-10) .60  
 p Valuec .04* .89 .09i
 p Valued .26 .67 .67ii
 p Valuee .02* .46 .84iii
Voiding frequency, daytime per 24 hours, median (interquartile range)
 Pretest (20/30) 8 (4-11) 8 (5-9) .65  
 Posttest (21/30) 6 (4-8) 7 (6-9) .35  
 Follow-up (19/30) 7 (3-10) 8 (6-9) .67  
 p Valuec .09 1.00 .20i
 p Valued .35 .93 .84ii
 p Valuee .08 .46 .53iii
Voiding frequency, nighttime per 24 hours, median (interquartile range)
 Pretest (20/30) 2 (1-3) 3 (2-4) .11  
 Posttest (21/30) 1 (1-2) 2 (1-3) .11  
 Follow-up (19/30) 2 (1-3) 2 (1-3) .66  
 p Valuec .05 .94 .20i
 p Valued .04* .23 .04ii,*
 p Valuee .50 .40 .95iii
ap Value presents the level of significance between the two groups. bp Value presents the level of significance between the two groups measured 
on the differences in frequency for each participant between ipretest and posttest, iiposttest and follow-up, iiipretest and follow-up, respectively. 
cp Value presents the level of significance within pretest and posttest of the two groups. dp Value presents the level of significance within posttest 
and follow-up of the two groups. ep Value presents the level of significance within pretest and follow-up of the two groups.
*Statistically significant, p < .05.
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Frequency of Voiding in the Nighttime. At 3 months, the 
median value of voiding frequency at night was reduced 
by 1 (50%) in the TG from pretest to posttest (p = .05). In 
the CG, the reduction was 1 (33%), not significant.
The frequency of nighttime voiding was reduced sig-
nificantly for the TG (p = .04) from posttest to follow-up, 
but not for the CG.
There were statistically significant differences (p = 
.04) between groups for each participant between posttest 
and follow-up, but not between groups at pretest, posttest, 
or follow-up.
Number of UI Episodes and Used Pads. The recorded num-
ber of UI episodes per 24 hours was very small (TG: pre-
test = 3, posttest = 0, follow-up = 1; CG: pretest = 1, 
posttest = 0, follow-up = 0). Likewise, the number of 
pads used per 24 hours was (TG: pretest = 1, posttest = 0, 
follow-up = 0; CG: pretest = 0, posttest = 0, follow-up = 
0). These numbers were too small for statistical analysis.
Digital Anal Palpation of PFM
The results are presented in Table 4.
PFM Function. At 3 months, the results measured on PFM 
function for the TG demonstrated significant improve-
ment (p < .01) from pretest to posttest compared with 
none in the CG (Figure 3), which was significantly better 
than the CG (p = .03).
At follow-up, only the TG improved statistically sig-
nificantly (p = .03) from pretest to follow-up.
PFM Strength. At 3 months, the results for the TG indi-
cated significant improvement (p < .01) from pretest to 
posttest, which was significantly better compared with 
the CG (p = .03). The TG also improved significantly 
from pretest to follow-up (p < .01), but not significantly 
more than the CG.
PFM Static Endurance. At 3 months, the results on PFM 
static endurance demonstrated a trend to statistically sig-
nificant improvement (p = .06) for the TG.
There was statistical significance (p = .03) between 
groups for each participant from pretest to posttest and 
from pretest to follow-up (p = .04).
PFM Dynamic Endurance. At 3 months, the results on PFM 
dynamic endurance demonstrated in the TG a trend to 
significant improvement (p = .05) from pretest to posttest 
but not in the CG. There were no significant differences 
between groups.
Adverse Events
No participants in either group reported any form of 
adverse event during the trial.
Discussion
This is, to the authors’ knowledge, the first RCT with 
6-month follow-up aiming to evaluate the effect of PFMT 
in men with LUTS after a stroke indicating beneficial 
effect. However, the effect was not statistically signifi-
cant between groups for patient-reported outcomes, in 
contrast to single-blinded observer-reported outcomes.
Despite the high prevalence of LUTS in poststroke 
men, the current study failed to include a large number of 
participants. Nevertheless, low dropout rate, high atten-
dance at PFMT sessions, and no adverse effects were 
demonstrated.
The current results measured on the DAN-PSS-1 
questionnaire indicated short-term effects within both 
groups, with most in the TG. The improvement in the CG, 
especially at posttest, can be explained not only by the 
placebo effect (Hrobjartsson & Gotzsche, 2010) but also 
by components such as self-monitoring voiding habits 
(Burgio, 2013) by rating the DAN-PSS-1 questionnaire 
and the voiding diary as well as learning effects resulting 
in self-PFMT by the digital anal palpation test.
The current results for the voiding frequency per 24 
hours are consistent with previous results evaluating the 
Figure 2. Results of pelvic floor muscle training measured 
on the Danish Prostate Symptom Score questionnaire, total 
score as presented as box plots.
Note. The symbols small circle and asterisk (*) in the box plot 
represents outliers, that is, results with a distance from the box 
ends (lower and upper quartile) that exceeds the height of the 
box (interquartile range) with a factor of more than 1.5 and 3, 
respectively. The numbers beside the symbols refers to the record 
number in the data.
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effect of PFMT in women with poststroke UI (Tibaek 
et al., 2005). A panel of experts has in consensus sug-
gested that, for healthy bladders, voiding frequency is 
approximately eight times per day and one or none per 
night (Lukacz, Whitcomb, Lawrence, Nager, & Luber, 
2009). This rate was for women; men usually have lower 
voiding daytime frequency (Mueller et al., 2005).
Several participants in the current study did not com-
plete the 3-day voiding diary, especially at the follow-up 
investigation, which weakens the reliability of the void-
ing diary as an outcome measure. At present, there is no 
optimal duration of days for rating voiding diaries in 
stroke patients.
The current short-term results for PFM function and 
PFM strength were consistent with the results for women 
(Tibaek et al., 2005). Moreover, the current study indi-
cated statistical significance between groups for each 
participant in PFM function, PFM strength, and PFM 
static endurance. It also indicated statistical significance 
for the long-term effect within groups for PFM function 
and PFM strength.
It is surprising that, although none of the participants 
in the TG had previous knowledge of PFMT (Table 2), 
the participants in TG demonstrated a higher attendance 
rate at the PFMT sessions than did men with UI to PFMT 
sessions over 3 months following prostatectomy or trans-
urethral resection of prostate (72% to 85% compared 
with the current 92%; Glazener et al., 2011).
Study Limitation
Several methodological issues in the current study need 
to be considered. The first issue is the small sample size 
of participants, leading to severe lack of statistical power. 
Table 4. Results of Pelvic Floor Muscle Training Measured on the Pelvic Floor Muscle in Poststroke Men.
Treatment group Control group p Valuea p Valueb
Pelvic floor muscle function, median (interquartile range)
 Pretest (30/30) 2 (2-2) 2 (2-2) 1.00  
 Posttest (28/30) 3 (2-3) 2 (2-2) .01*  
 Follow-up (24/30) 2 (2-3) 2 (2-2) .25  
 p Valuec <.01* 1.00 .03i,*
 p Valued .48 1.00 .53ii
 p Valuee .03* 1.00 .15iii
Pelvic floor muscle strength, median (interquartile range)
 Pretest (30/30) 3 (2-4) 3 (2-4) 1.00  
 Posttest (28/30) 5 (4-6) 4 (4-5) .07  
 Follow-up (24/30) 5 (4-6) 4 (3-5) .15  
 p Valuec <.01* .10 .03i,*
 p Valued .45 .15 .61ii
 p Valuee <.01* .94 .17iii
Pelvic floor muscle static endurance, seconds, median (interquartile range)
 Pretest (30/30) 14 (8-26) 24 (13-30) .33  
 Posttest (28/30) 29 (14-60) 19 (7-29) .10  
 Follow-up (24/30) 30 (14-60) 25 (12-32) .33  
 p Valuec .06 .21 .03i,*
 p Valued .86 .74 .82ii
 p Valuee .12 .34 .04iii,*
Pelvic floor muscle dynamic endurance, seconds, median (interquartile range)
 Pretest (30/30) 40 (21-40) 32 (19-40) .71  
 Posttest (28/30) 40 (40-40) 40 (35-40) .23  
 Follow-up (24/30) 40 (37-40) 40 (30-40) .65  
 p Valuec .05 .21 .29i
 p Valued .94 .74 .57ii
 p Valuee .18 .34 .91iii
ap Value presents the level of significance between the two groups. bp Value presents the level of significance between the two groups measured 
on the differences in PFM function, strength, static, and dynamic endurance, for each participant between ipretest and posttest, iiposttest and 
follow-up test, iiipretest and follow-up, respectively. cp Value presents the level of significance within pretest and posttest of the two groups. dp 
Value presents the level of significance within posttest and follow-up of the two groups. ep Value presents the level of significance within pretest 
and follow-up of the two groups.
*Statistically significant, p < .05.
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Approximately 1 out of 10 of those invited did not 
respond to the current invitation, half reported that they 
did not have LUTS, 1 out of 5 had previous LUTS but 
with no change in the condition after the stroke, and 1 out 
of 10 had LUTS but lacked resources to participate or did 
not want to do so.
The current data raise the question, “Why was it so 
difficult to involve these potential participants?” Perhaps 
the men regard their symptoms as normal (Lai, Wun, 
Luo, & Pang, 2011)? Perhaps they were too embarrassed 
or ashamed to report LUTS? Perhaps they had developed 
coping mechanisms which controlled their symptoms? 
Perhaps they did not like PFMT?
Identification of factors and barriers may improve the 
understanding of the attitude of poststroke men to LUTS 
and PFMT as the problem is significant in a substantial 
proportion of stroke patients. Likewise, an analysis of 
baseline characteristics for possible differences between 
included and nonincluded men may provide valuable 
information on this selection mechanism.
A second issue is the relatively large decrease mea-
sured at the follow-up compared with posttest. Almost 
all self-reported outcome data were worse in the TG at 
6-month follow-up; for the PFMT the increased effect 
during intervention was stopped and the outcome data 
were at the same level as at posttest. All participants in 
the TG were strongly recommended to continue daily 
PFMT using their home-training program as in the 
intervention. However, education of participants is 
important to ensure consistency of the training and its 
monitoring. Perhaps using a training diary, PT tele-
phone contact, or for some electronic knowledge par-
ticipants advanced Internet methods might be important 
training supports (Piron, Tonin, Trivello, Battistin, & 
Dam, 2004).
The third issue is the validity and reliability of the 
digital anal palpation measurement of PFM. This meth-
odological study remains in neurologic as well as non-
neurologic healthy men and women with LUTS (Kruger, 
Dietz, Budgett, & Dumoulin, 2014).
The participants reported no side effects. However, 
side effects can occur and be negative (dry mouth, consti-
pation, or irrigative symptoms) or positive (increased 
energy, absence of urinary infection and of obstipation, 
improved sexual function and satisfaction). Nonetheless, 
while many positive effects are known of physical activ-
ity, little is known about its effects related to PFMT.
By evaluating the effect of PFMT as a single interven-
tion while an intervention with multiple components, 
such as urge suppression strategies (Burgio, 2013) and 
fluid restriction, may increase the effect. However, to 
understand the underlying mechanism of PFMT, it is 
needed to investigate the relative contributions of the 
individual components. Likewise, evaluating the effect of 
PFMT on LUTS in stroke patients with mild to moderate 
cognitive impairment needs future research.
Figure 3. Results of pelvic floor muscle training measured on the pelvic floor muscle function and strength in poststroke men.
Note. The symbols small circle and asterisk (*) in the box plot represents outliers, that is, results with a distance from the box ends (lower and 
upper quartile) that exceeds the height of the box (interquartile range) with a factor of more than 1.5 and 3, respectively. The numbers beside 
the symbols refers to the record number in the data.
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Conclusion
The results of this study indicated that it is difficult to 
include men with stroke in a PFMT study; however, when 
they were included they were highly motivated and com-
pleted the study. The results of PFMT in poststroke men 
indicated its effectiveness by reducing LUTS and fre-
quency of voidings, although no statistical significance 
was reported between groups except for PFM function 
and strength. It is recommended that further studies with 
larger sample sizes need to be carried out to understand 
the barriers to participation by men in such research and 
for exploring how PFMT works in men with poststroke 
LUTS.
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